Regeneron partners with bluebird on cancer therapies, invests $100 million

The company will use its VelociSuite platform in order to help find human antibodies as well as T cell receptors and bluebird will contribute its expertise in gene transfer and cell therapy
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news